Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin (pin regimen)in patients with urothelial cancer who have received prior cisplatin-based therapy

被引：0
|
作者：
不详
机构：
来源：
EUROPEAN UROLOGY SUPPLEMENTS | 2005年 / 4卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：139 / 139
页数：1
相关论文
共 50 条
  • [41] Predictive factors of response to cisplatin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer
    Sengelov, L
    Kamby, C
    Geertsen, F
    Andersen, LJ
    von der Maase, H
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 46 (05) : 357 - 364
  • [42] Biweekly carboplatin/gemcitabine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: Report of efficacy, quality of life and geriatric assessment
    Bamias, Aristotle
    Lainakis, George
    Kastritis, Efstathios
    Antoniou, Nikos
    Alivizatos, Gerassimos
    Koureas, Andreas
    Chrisofos, Michael
    Skolarikos, Andreas
    Karayiotis, Evangelos
    Dimopoulos, Meletios A.
    ONCOLOGY, 2007, 73 (5-6) : 290 - 297
  • [43] Salvage chemotherapy with paclitaxel and gemcitabine plus nedaplatin (TGN) as part of multidisciplinary therapy in patients with heavily pretreated cisplatin-refractory germ cell tumors
    Takumi Shiraishi
    Terukazu Nakamura
    Kazuya Mikami
    Natsuki Takaha
    Akihiro Kawauchi
    Tsuneharu Miki
    International Journal of Clinical Oncology, 2009, 14 : 436 - 441
  • [44] Salvage chemotherapy with paclitaxel and gemcitabine plus nedaplatin (TGN) as part of multidisciplinary therapy in patients with heavily pretreated cisplatin-refractory germ cell tumors
    Shiraishi, Takumi
    Nakamura, Terukazu
    Mikami, Kazuya
    Takaha, Natsuki
    Kawauchi, Akihiro
    Miki, Tsuneharu
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2009, 14 (05) : 436 - 441
  • [45] Re-treating with carboplatin and paclitaxel as first line therapy for recurrent endometrial cancer in patients who have previously received this regimen in the adjuvant setting
    Cadoo, K.
    Halpenny, D.
    Phillips, M.
    Aghajanian, C.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S552 - S552
  • [46] A nomogram predicting survival of patients (pts) with metastatic or unresectable urothelial cancer (UC) treated with cisplatin-based chemotherapy
    Bajorin, D. F.
    Ostrovnaya, I.
    Iasonos, A.
    Milowsky, M. I.
    Boyle, M.
    Riches, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [47] Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy
    Galsky, Matthew D.
    Moshier, Erin
    Krege, Susan
    Lin, Chia-Chi
    Hahn, Noah
    Ecke, Thorsten
    Sonpavde, Guru
    Pond, Gregory
    Godbold, James
    Oh, William K.
    Bamias, Aristotle
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2014, 32 (01) : 48.e1 - 48.e8
  • [48] Docetaxel: Response in patients who have received at least two prior chemotherapy regimes for metastatic breast cancer
    Archer, CD
    Lowdell, C
    Sinnett, HD
    English, J
    Khan, S
    Coombes, RC
    EUROPEAN JOURNAL OF CANCER, 1998, 34 (06) : 816 - 819
  • [49] Short Hydration Regimen with a Modified Dose of Magnesium Supplementation for Lung Cancer Patients Receiving Cisplatin-Based Chemotherapy
    Hase, T.
    Miyazaki, M.
    Ichikawa, K.
    Yogo, N.
    Ozawa, N.
    Ando, M.
    Morise, M.
    Sato, M.
    Kondo, M.
    Yamada, K.
    Hasegawa, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S880 - S880
  • [50] CARBOPLATIN, METHOTREXATE, AND VINBLASTINE IN PATIENTS WITH BLADDER-CANCER WHO WERE INELIGIBLE FOR CISPLATIN-BASED CHEMOTHERAPY
    BELLMUNT, J
    ALBANELL, J
    GALLEGO, OS
    RIBAS, A
    VICENTE, P
    CARULLA, J
    DETORRES, J
    MOROTE, J
    LOPEZ, M
    SOLE, LA
    CANCER, 1992, 70 (07) : 1974 - 1979
12345